NasdaqGS - Delayed Quote USD

Editas Medicine, Inc. (EDIT)

5.20 +0.03 (+0.58%)
At close: May 31 at 4:00 PM EDT
5.28 +0.08 (+1.54%)
Pre-Market: 8:59 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
69,407.00
78,123.00
19,712.00
25,544.00
90,732.00
--
Operating Expense
254,618.00
247,304.00
245,662.00
218,690.00
225,572.00
--
Operating Income
-185,211.00
-169,181.00
-225,950.00
-193,146.00
-134,840.00
--
Net Non Operating Interest Income Expense
19,092.00
17,566.00
5,518.00
607.00
2,605.00
--
Other Income Expense
-14.00
-1,604.00
1,293.00
37.00
16,259.00
--
Pretax Income
-166,133.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
--
Net Income Common Stockholders
-166,133.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
--
Diluted NI Available to Com Stockholders
-166,133.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
--
Basic EPS
-2.07
-2.02
-3.21
-2.85
-1.98
--
Diluted EPS
-2.07
-2.02
-3.21
-2.85
-1.98
--
Basic Average Shares
79,219.30
75,965.63
68,664.82
67,619.39
58,609.39
--
Diluted Average Shares
79,219.30
75,965.63
68,664.82
67,619.39
58,609.39
--
Total Operating Income as Reported
-185,211.00
-169,181.00
-225,950.00
-193,146.00
-134,840.00
--
Total Expenses
254,618.00
247,304.00
245,662.00
218,690.00
225,572.00
--
Net Income from Continuing & Discontinued Operation
-166,133.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
--
Normalized Income
-166,133.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
--
Interest Income
19,092.00
17,566.00
5,518.00
607.00
2,605.00
--
Interest Expense
--
--
--
--
--
-7,313.00
Net Interest Income
19,092.00
17,566.00
5,518.00
607.00
2,605.00
--
EBIT
-185,211.00
-169,181.00
-225,950.00
-193,146.00
-134,840.00
--
EBITDA
-179,282.00
-163,117.00
-219,613.00
-188,093.00
-130,881.00
--
Reconciled Depreciation
5,929.00
6,064.00
6,337.00
5,053.00
3,959.00
--
Net Income from Continuing Operation Net Minority Interest
-166,133.00
-153,219.00
-220,432.00
-192,502.00
-115,976.00
--
Normalized EBITDA
-179,282.00
-163,117.00
-219,613.00
-188,093.00
-130,881.00
--
12/31/2019 - 2/3/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NTLA Intellia Therapeutics, Inc.
21.38
-3.26%
 
BEAM Beam Therapeutics Inc.
23.81
-1.16%
 
CRSP CRISPR Therapeutics AG
53.74
-0.59%
 
CRBU Caribou Biosciences, Inc.
2.8800
+1.05%
 
VERV Verve Therapeutics, Inc.
5.19
+0.97%
 
BLUE bluebird bio, Inc.
0.9034
+0.87%
 
ARCT Arcturus Therapeutics Holdings Inc.
38.81
+0.86%
 
DNA Ginkgo Bioworks Holdings, Inc.
0.5285
-5.51%
 
PRME Prime Medicine, Inc.
6.48
-0.31%
 
IOVA Iovance Biotherapeutics, Inc.
8.89
-1.28%